pre-IPO PHARMA

antengene-corporation PRESS RELEASE ARCHIVE

Nov 20, 2020

Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange


Jul 19, 2020

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization


Jun 8, 2020

Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer


Apr 13, 2020

Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions


Jan 6, 2020

Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer



Nov 6, 2019

Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364


Apr 8, 2019

Antengene Corporation Announces Establishment of U.S. Subsidiary and Collaboration with the Baruch S. Blumberg Institute


Jan 1, 2019

Antengene Corporation Raises $120 Million in Series B Financing


Google Analytics Alternative